Implementierungsleitfaden Therapieziele Onkologie
1.0.0-ballot - Ballot Germany

Implementierungsleitfaden Therapieziele Onkologie - Local Development build (v1.0.0-ballot) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

: HER2/neu-Status – negativ (Beispiel)

Raw xml | Download


<Observation xmlns="http://hl7.org/fhir">
  <id value="ObsHER2Mamma"/>
  <language value="de"/>
  <text>
    <status value="generated"/>
    <div xml:lang="de" lang="de"><hr/><p><b>German</b></p><hr/><p class="res-header-id"><b>Generated Narrative: Observation ObsHER2Mamma</b></p><a name="ObsHER2Mamma"> </a><a name="hcObsHER2Mamma"> </a><p><b>status</b>: Final</p><p><b>code</b>: <span title="Codes:{http://loinc.org 48676-1}">HER2 Ag [Interpretation] in Tissue</span></p><p><b>subject</b>: <a href="Patient-PatientinMamma.html">Sabine Baumann  Female, DoB: 1977-06-24</a></p><p><b>effective</b>: 2025-09-17</p><p><b>value</b>: <span title="Codes:{http://loinc.org LA6577-6}, {https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-obds N}, {https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-leitlinie negativ}">Negative</span></p><p><b>note</b>: </p><blockquote><div><p>Immunhistochemie 1+ → HER2-negativ; keine In-situ-Hybridisierung erforderlich.</p>
</div></blockquote><p><b>specimen</b>: <a href="Specimen-SpecimenBiopsieMamma.html">Specimen: status = available; type = Specimen from breast obtained by core needle biopsy</a></p></div>
  </text>
  <status value="final"/>
  <code>
    <coding>
      <system value="http://loinc.org"/>
      <code value="48676-1"/>
      <display value="HER2 Ag [Interpretation] in Tissue"/>
    </coding>
  </code>
  <subject>🔗 
    <reference value="Patient/PatientinMamma"/>
  </subject>
  <effectiveDateTime value="2025-09-17"/>
  <valueCodeableConcept>
    <coding>
      <system value="http://loinc.org"/>
      <code value="LA6577-6"/>
      <display value="Negative"/>
    </coding>
    <coding>
      <system
              value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-obds"/>
      <code value="N"/>
      <display value="negativ"/>
    </coding>
    <coding>
      <system
              value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-mamma-her2neu-status-leitlinie"/>
      <code value="negativ"/>
      <display value="HER2-negativ"/>
    </coding>
  </valueCodeableConcept>
  <note>
    <text
          value="Immunhistochemie 1+ → HER2-negativ; keine In-situ-Hybridisierung erforderlich."/>
  </note>
  <specimen>🔗 
    <reference value="Specimen/SpecimenBiopsieMamma"/>
  </specimen>
</Observation>